TScan Therapeutics, Inc. - 8-K Filing
TScan Therapeutics entered into separation agreements with CFO Jason Amello and CMO Chrystal Louis effective on the earlier of November 1, 2026 or when they commence new employment. (Items: 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Offi)
Tickers: $TCRX